Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

GDX012 · TAK-012

Cell therapy · Kills target cells, directed at tumor cells · developed by TAKEDA PHARMACEUTICAL CO

Phase 1/2 Most advanced trial (none active)

TAK Developer

1 Registered trials

What is GDX012?

GDX012 is an off-the-shelf allogeneic Vd1 gamma-delta T-cell therapy that directly kills tumor cells and activates cytotoxic T-lymphocyte responses. The cells secrete interferon-gamma and recognize cancer cells without requiring MHC-mediated antigen presentation. It is studied in acute myeloid leukemia and other leukemias.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: TAK-012
Drug type: Cell therapy
Targets: tumor cells (antigen)
Mechanism: Kills target cells, directed at tumor cells
Pathways: immune_activation, cytotoxic_T_lymphocyte_response
Therapy area: Oncology
Developer: TAKEDA PHARMACEUTICAL CO (TAK)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05886491	Phase 1/2	Leukemia	Terminated	TAK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Leukemia

More from TAKEDA PHARMACEUTICAL CO

Maribavir FDA approved Susoctocog Alfa FDA approved Vedolizumab FDA approved Vonicog Alfa FDA approved Elritercept Phase 3 IGI Phase 3 Mezagitamab Phase 3 MNI-792 Phase 1 Pevonedistat Phase 2/3 Soticlestat Phase 3 TAK-186 Phase 1/2 TAK-188 Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the TAK page.

Follow TAK, the company behind GDX012

See TAK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TAK catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z